Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410033 | 0.94 | HTT (0.58) | MAPTUSP2HTTPOLBMEN1 | |
| SCHEMBL4256753 | 0.87 | HTT (0.58) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL4249933 | 0.87 | HTT (0.73) | MAPTUSP2HTTKMT2ATSHR | |
| SCHEMBL4250777 | 0.86 | HTT (0.55) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL8264027 | 0.86 | USP2 (0.57) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL1764005 | 0.85 | MAPT (0.58) | MAPTHTTPOLBTP53THRB | |
| SCHEMBL4258732 | 0.84 | USP2 (0.53) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL1763825 | 0.81 | MAPT (0.56) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL10184668 | 0.81 | POLB (0.52) | MAPTUSP2HTTPOLBTP53 | |
| SCHEMBL8409946 | 0.80 | HTT (0.57) | MAPTUSP2HTTPOLBTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | MAPT 692/4885USP2 3572/4885HTT 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.